Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment-Reference-Cited by-同舟云学术

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Published:2015-12-10 Issue:24 Volume:126 Page:2578-2584
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zugmaier Gerhard¹,Gökbuget Nicola²,Klinger Matthias¹,Viardot Andreas³,Stelljes Matthias⁴,Neumann Svenja⁵,Horst Heinz-A.⁵,Marks Reinhard⁶,Faul Christoph⁷,Diedrich Helmut⁸,Reichle Albrecht⁹,Brüggemann Monika⁵,Holland Chris¹⁰,Schmidt Margit¹,Einsele Hermann¹¹,Bargou Ralf C.¹²,Topp Max S.¹¹

Affiliation:

1. Amgen Research (Munich), Munich, Germany;

2. Department of Medicine II, Goethe University Frankfurt, Frankfurt, Germany;

3. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;

4. Department of Medicine A, University of Münster, Münster, Germany;

5. Department of Medicine II, Christian-Albrechts-Universität zu Kiel, Kiel, Germany;

6. Department of Medicine I, Albert-Ludwigs-Universität Frieburg, Freiburg, Germany;

7. Department of Medicine II, Eberhard Karls Universität Tübingen, Tübingen, Germany;

8. Department of Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany;

9. Department of Medicine III, University of Regensburg, Regensburg, Germany;

10. Amgen, Rockville, MD; and

11. Department of Medicine II and

12. Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany

Abstract

Key Points Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/24/2578/1389787/2578.pdf

Reference15 articles.

1. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.;Tavernier;Leukemia,2007

2. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.;Oriol;Haematologica,2010

3. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.;Fielding;Blood,2007

4. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.;Kantarjian;Cancer,2010

5. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.;Gökbuget;Blood,2012

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma;Blood Advances;2024-02-13

2. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience;Frontiers in Immunology;2023-09-22

3. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review;Leukemia & Lymphoma;2023-08

4. Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance;eLife;2023-07-25

5. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody;Cancer Management and Research;2023-07